The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Desmopressin (Noqdirna®) has been rejected for use in the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. The submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance.
Evolocumab (Repatha®) has been accepted for restricted use in adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet, in combination to reach treatment goals or alone when other treatments are not tolerated. The restriction limits use to specialist use in patients at high cardiovascular risk.
Pitolisant (Wakix®) has been rejected for the treatment of narcolepsy with or without cataplexy in adults. The manufacturer failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - January 2017||Drug Safety Update - February 2017 »|